Medtronic plc (MDT) recently announced positive results demonstrating the safety and efficacy of the Affera Mapping and Ablation System with the Sphere-9 Catheter. The SPHERE Per-AF study, an FDA Investigational Device Exemption (“IDE”) pivotal trial, compared Sphere-9 to the conventional Thermocool SmartTouch SF radiofrequency ablation catheter with the Carto 3 System.The late-breaking clinical data was presented at the Heart Rhythm Society 2024 Annual Meeting and simultaneously published in Nature Medicin ...